Brief: Cognition Therapeutics Completes Enrollment Of CT1812 Phase 2 SEQUEL Study For Mild-To-Moderate Alzheimer’S Disease
09/02/2023 19:02
Feb 9 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS COMPLETES ENROLLMENT OF CT1812
PHASE 2
SEQUEL STUDY FOR MILD-TO-MODERATE ALZHEIMER’S DISEASE
* COGNITION THERAPEUTICS INC - TOPLINE RESULTS FROM SEQUEL
ARE
EXPECTED MID-2023
Source text for Eikon: ID:nGNX9qc0Lx
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB